Levels of minimal residual disease in chronic myelogenous leukemia (CML) patients in complete cytogenetic remission after interferon-alpha-therapy correlate with risk of relapse.

被引：0
|
作者：
Hochhaus, A
Lin, F
Reiter, A
Skladny, H
Shepherd, PCA
Sill, H
Allan, NC
Hehlmann, R
Goldman, JM
Cross, NCP
机构：
[1] UNIV HEIDELBERG,KLINIKUM MANNHEIM,MED KLIN 3,D-6900 HEIDELBERG,GERMANY
[2] HAMMERSMITH HOSP,LRF LEUKAEMIA UNIT,LONDON,ENGLAND
[3] MRC,HUMAN GENET UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND
[4] GRAZ UNIV,DEPT HAMATOL,A-8010 GRAZ,AUSTRIA
来源：
EXPERIMENTAL HEMATOLOGY | 1996年 / 24卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：579 / 579
页数：1
相关论文
共 50 条
  • [1] Molecular heterogeneity in complete cytogenetic responders after interferon-alpha-therapy of chronic myelogenous leukemia: Levels of minimal residual disease predict risk of relapse.
    Hochhaus, A
    Reiter, A
    Skladny, H
    Lin, F
    Reichert, A
    Saussele, S
    Shepherd, PCA
    Allan, NC
    Hehlmann, R
    Goldman, JM
    Cross, NCP
    BLOOD, 1996, 88 (10) : 2644 - 2644
  • [2] Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia:: low levels of minimal residual disease are associated with continuing remission
    Hochhaus, A
    Reiter, A
    Saussele, S
    Reichert, A
    Emig, M
    Kaeda, J
    Schultheis, B
    Berger, U
    Shepherd, PCA
    Allan, NC
    Hehlmann, R
    Goldman, JM
    Cross, NCP
    BLOOD, 2000, 95 (01) : 62 - 66
  • [3] Molecular heterogeneity in complete cytogenetic responders on interferon-α therapy of CML:: Levels of minimal residual disease predict risk of relapse
    Hochhaus, A
    Reichert, A
    Saussele, S
    Reiter, A
    Emig, H
    Hehlmann, R
    Goldman, JM
    Cross, NCP
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 283 - 283
  • [4] Lymphoid blast crisis in patients with chronic myelogenous leukemia in complete cytogenetic remission after interferon therapy.
    Guilhot, F
    Delwail, V
    Lacotte, L
    Brizard, A
    Chomel, JC
    Kitzis, A
    BLOOD, 1995, 86 (10) : 3168 - 3168
  • [5] Low levels of residual disease predict durable cytogenetic remission in chronic myelogenous leukemia patients responding to interferon-α.
    Hochhaus, A
    Reiter, A
    Saussele, S
    Reichert, A
    Emig, M
    Kaeda, J
    Schultheis, B
    Berger, U
    Shepherd, PCA
    Allan, NC
    Hehlmann, R
    Goldman, JM
    Cross, NCP
    BLOOD, 1999, 94 (10) : 531A - 531A
  • [6] MINIMAL RESIDUAL DISEASE RESIDES IN BONE-MARROW BUT NOT PERIPHERAL-BLOOD STEM-CELLS OF A PATIENT WITH CHRONIC MYELOGENOUS LEUKEMIA IN COMPLETE CYTOGENETIC REMISSION AFTER INTERFERON-ALPHA THERAPY
    ROVITO, MA
    LUCE, M
    NOWELL, PC
    BESA, EC
    BLOOD, 1993, 82 (10) : A641 - A641
  • [7] ALPHA-INTERFERON (IFN) RESULTS IN HIGH COMPLETE CYTOGENETIC RESPONSE RATE IN PATIENTS WITH CYTOGENETIC-ONLY RELAPSE OF CHRONIC MYELOGENOUS LEUKEMIA (CML) AFTER MARROW TRANSPLANTATION (BMT)
    HIGANO, C
    RASKIND, W
    FLOWERS, M
    BLOOD, 1993, 82 (10) : A169 - A169
  • [8] Significance of Rising Levels of Minimal Residual Disease in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (Ph plus CML) in Complete Cytogenetic Response (CGCR)
    Kantarjian, Hagop M.
    Shan, Jianqin
    Jones, Dan
    O'Brien, Susan
    Rios, Mary Beth
    Jabbour, Elias
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 169 - 170
  • [9] Chronic myelocytic leukemia patients achieving complete cytogenetic conversion under interferon alpha therapy: Minimal residual disease follow-up
    BilhouNabera, C
    Marit, G
    Gharbi, MJ
    Salzes, S
    Mahon, FX
    Broustet, A
    Reiffers, J
    Bernard, P
    LEUKEMIA, 1995, 9 (12) : 2067 - 2070
  • [10] Adjuvant Treatment with Alpha Interferon (IFN) for Patients at High Risk for Relapse after Allogeneic Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
    Bezerra, Evandro Dantas
    Radich, Jerald
    Flowers, Mary E.
    Chielins, Debbie
    Higano, Celestia
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S238 - S238
12345